Diagnosis and Management of Non-ST-Elevation Myocardial Infarction (NSTEMI)

Laboratory Tests

• Serial cardiac troponin measurements are the cornerstone laboratory test for diagnosing and managing NSTEMI, with the first sample taken at presentation and follow-up samples at 1-3 hours after the initial test to identify a rising and/or falling pattern, as recommended by the European Society of Cardiology 1
• Cardiac Troponin (high-sensitivity preferred) should be measured initially at presentation and serially at 1-3 hours after the first test, with additional measurement at 3-6 hours if initial tests are inconclusive but clinical suspicion remains high, according to the European Heart Journal 1
• Central laboratory assays are preferred over point-of-care testing for cardiac troponin measurement, as stated by the American Heart Association 2
• A 12-lead ECG should be obtained immediately upon presentation and repeated if symptoms recur or clinical suspicion remains high, with consideration of additional leads (V3R, V4R, V7-V9) if standard leads are inconclusive, as recommended by the European Society of Cardiology 1
• Complete Blood Count (CBC) should include hemoglobin and hematocrit to assess for anemia, which may exacerbate NSTEMI, and white blood cell count, which is associated with worse outcomes, as reported by the European Heart Journal 3
• Renal Function Tests, including serum creatinine and eGFR, are essential for risk stratification and medication dosing, and are part of the GRACE risk score calculation, as stated by the European Society of Cardiology 1
• Natriuretic Peptides (BNP or NT-proBNP) provide prognostic information regarding risk of death and heart failure, and help identify patients at higher risk for adverse outcomes, as reported by the European Heart Journal 1
• High-sensitivity C-reactive protein (hs-CRP) may provide additional prognostic information in some cases, as stated by the European Society of Cardiology 1

Risk Stratification

• The GRACE or TIMI risk scores, which incorporate laboratory values, should be used for risk stratification, with high-risk patients (GRACE >140 or TIMI >4) receiving early invasive strategy, as recommended by the American College of Cardiology 2
• Troponin should be interpreted as a quantitative marker, with the higher level indicating greater likelihood of MI, and a rising and/or falling pattern is essential for diagnosis, as reported by the European Heart Journal 3

Timing and Monitoring

• The first troponin measurement should be obtained within 6 hours of hospital arrival, as stated by the American Heart Association 2
• Patients should be admitted to a monitored unit with continuous rhythm monitoring until NSTEMI is confirmed or ruled out, as recommended by the European Society of Cardiology 1